设定选择：PI3K 抑制剂能否规避 CDK4/6 抑制剂耐药？
Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
机构信息
Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Abramson Cancer Center, Philadelphia, Pennsylvania.
出版信息
Clin Cancer Res. 2021 Jan 15;27(2):371-373. doi: 10.1158/1078-0432.CCR-20-3624. Epub 2020 Nov 3.
Abstract
PI3K and CDK4/6 inhibitors (CDK4/6i) are targeted therapies approved to treat advanced breast cancer; CDK4/6is are more widely used. Here, we discuss trials that examine PI3K inhibitors with novel drug combinations, including a CDK4/6i, given data implicating the pathway in CDK 4/6 resistance..
摘要
PI3K 和 CDK4/6 抑制剂（CDK4/6i）是被批准用于治疗晚期乳腺癌的靶向治疗药物；CDK4/6i 更为常用。在此，我们讨论了包含 CDK4/6i 的新型药物组合中 PI3K 抑制剂的试验，这些数据提示该通路与 CDK4/6 耐药有关。
相似文献
1
Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?设定选择：PI3K 抑制剂能否规避 CDK4/6 抑制剂耐药？
Clin Cancer Res. 2021 Jan 15;27(2):371-373. doi: 10.1158/1078-0432.CCR-20-3624. Epub 2020 Nov 3.
2
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.液体活检中检测到的 PI3K 突变与转移性乳腺癌患者对 CDK4/6 抑制剂的敏感性降低有关。
Pharmacol Res. 2021 Jan;163:105241. doi: 10.1016/j.phrs.2020.105241. Epub 2020 Oct 10.
3
Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.转移性激素受体阳性乳腺癌中细胞周期蛋白依赖性激酶抑制后的治疗：耐药机制和新的治疗策略。
Cancer. 2020 Aug 1;126(15):3400-3416. doi: 10.1002/cncr.32931. Epub 2020 May 19.
4
The Role of CDK4/6 Inhibition in Breast Cancer.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制在乳腺癌中的作用
Oncologist. 2015 May;20(5):483-90. doi: 10.1634/theoncologist.2014-0443. Epub 2015 Apr 15.
5
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.一项在 HR 阳性、HER2 阴性的绝经前晚期乳腺癌女性中，联合使用阿培利司或玻玛西林与他莫昔芬加戈舍瑞林的 Ib 期研究。
Clin Cancer Res. 2021 Jan 15;27(2):408-417. doi: 10.1158/1078-0432.CCR-20-1008. Epub 2020 Jul 27.
6
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR/HER2 Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).依维莫司、来曲唑和瑞博西利用于 CDK4/6 抑制剂治疗后进展的 HR/HER2 阳性晚期乳腺癌女性的 I/II 期试验（TRINITI-1）。
Clin Cancer Res. 2021 Aug 1;27(15):4177-4185. doi: 10.1158/1078-0432.CCR-20-2114. Epub 2021 Mar 15.
7
Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis.基于激素受体阳性/HER2 阴性晚期乳腺癌的内分泌治疗：系统评价和网络荟萃分析。
ESMO Open. 2020 Aug;5(4). doi: 10.1136/esmoopen-2020-000842.
8
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.FAT1 肿瘤抑制因子丢失通过 Hippo 通路促进 CDK4/6 抑制剂耐药性。
Cancer Cell. 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006.
9
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility.CDK4/6 抑制剂生物标志物全景：最相关的反应或耐药生物标志物，用于进一步研究和潜在的临床应用。
Crit Rev Oncol Hematol. 2023 Dec;192:104148. doi: 10.1016/j.critrevonc.2023.104148. Epub 2023 Oct 1.
10
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.针对激活的 PI3K/mTOR 信号通路克服了激素受体阳性乳腺癌临床前模型中 CDK4/6 为基础的治疗的获得性耐药。
Breast Cancer Res. 2020 Aug 14;22(1):89. doi: 10.1186/s13058-020-01320-8.
引用本文的文献
1
Functional Analysis of the PI3K/AKT/mTOR Pathway Inhibitor, Gedatolisib, Plus Fulvestrant with and Without Palbociclib in Breast Cancer Models.PI3K/AKT/mTOR通路抑制剂Gedatolisib联合氟维司群以及联合或不联合帕博西尼在乳腺癌模型中的功能分析
Int J Mol Sci. 2025 Jun 18;26(12):5844. doi: 10.3390/ijms26125844.
2
PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer.PTEN的NEDDylation加重乳腺癌对CDK4/6抑制剂的耐药性。
Oncogene. 2025 Jun 18. doi: 10.1038/s41388-025-03468-z.
3
The regulatory role of CDK4/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (Review).CDK4/6抑制剂在肿瘤免疫中的调控作用及肿瘤免疫治疗的潜在价值（综述）
Int J Mol Med. 2025 Aug;56(2). doi: 10.3892/ijmm.2025.5564. Epub 2025 Jun 13.
4
Actionable mutations in early-stage ovarian cancer according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT): a descriptive analysis on a large prospective cohort.根据分子靶点临床可操作性的ESMO量表（ESCAT）得出的早期卵巢癌可操作突变：一项大型前瞻性队列的描述性分析
ESMO Open. 2025 Jan;10(1):104090. doi: 10.1016/j.esmoop.2024.104090. Epub 2024 Dec 19.
5
Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer - A Clinical Review.揭示细胞周期蛋白依赖性激酶4和6抑制剂在激素受体阳性/人表皮生长因子阴性晚期乳腺癌进展之外的潜力——一项临床综述
Curr Treat Options Oncol. 2024 Dec;25(12):1517-1537. doi: 10.1007/s11864-024-01259-4. Epub 2024 Nov 30.
6
Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway.乳腺癌的预测、预防和个体化医学：针对 PI3K 通路。
J Transl Med. 2024 Jan 3;22(1):15. doi: 10.1186/s12967-023-04841-w.
7
HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma.高迁移率族蛋白A1（HMGA1）通过磷脂酰肌醇-3-激酶/雷帕霉素靶蛋白（PI3K/mTOR）信号通路增强肝内胆管癌中帕博西尼的疗效。
Biomark Res. 2023 Mar 29;11(1):33. doi: 10.1186/s40364-023-00473-w.
8
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer.针对 ER+ 乳腺癌的 PI3K/AKT/mTOR 通路药物治疗。
Int J Mol Sci. 2023 Feb 24;24(5):4522. doi: 10.3390/ijms24054522.
9
Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions.靶向细胞周期蛋白依赖性激酶在肉瘤治疗中的应用：当前观点与未来方向
Front Oncol. 2023 Jan 19;13:1095219. doi: 10.3389/fonc.2023.1095219. eCollection 2023.
10
PFKFB4 facilitates palbociclib resistance in oestrogen receptor-positive breast cancer by enhancing stemness.PFKFB4通过增强干性促进雌激素受体阳性乳腺癌对哌柏西利的耐药性。
Cell Prolif. 2023 Jan;56(1):e13337. doi: 10.1111/cpr.13337. Epub 2022 Sep 20.
本文引用的文献
1
On the Rise of Cyclin-Dependent Kinase Inhibitors in Breast Cancer: .细胞周期蛋白依赖性激酶抑制剂在乳腺癌中的兴起：.
Breast Cancer Manag. 2020 Jun;9(2). doi: 10.2217/bmt-2020-0005. Epub 2020 Apr 30.
2
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR Advanced Breast Cancer.瑞博西尼联合氟维司群以及瑞博西尼联合氟维司群加PI3K抑制剂（阿培利司或布帕利司）用于激素受体阳性晚期乳腺癌的Ib期研究
Clin Cancer Res. 2021 Jan 15;27(2):418-428. doi: 10.1158/1078-0432.CCR-20-0645. Epub 2020 Sep 4.
3
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.针对激活的 PI3K/mTOR 信号通路克服了激素受体阳性乳腺癌临床前模型中 CDK4/6 为基础的治疗的获得性耐药。
Breast Cancer Res. 2020 Aug 14;22(1):89. doi: 10.1186/s13058-020-01320-8.
4
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.一项在 HR 阳性、HER2 阴性的绝经前晚期乳腺癌女性中，联合使用阿培利司或玻玛西林与他莫昔芬加戈舍瑞林的 Ib 期研究。
Clin Cancer Res. 2021 Jan 15;27(2):408-417. doi: 10.1158/1078-0432.CCR-20-1008. Epub 2020 Jul 27.
5
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.瑞博西利联合内分泌治疗乳腺癌的总生存。
N Engl J Med. 2019 Jul 25;381(4):307-316. doi: 10.1056/NEJMoa1903765. Epub 2019 Jun 4.
6
Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.阿培利司治疗 - 突变型、激素受体阳性晚期乳腺癌。
N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904.
7
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.来曲唑联合内分泌治疗激素受体阳性、晚期乳腺癌的绝经前妇女（MONALEESA-7）：一项随机 3 期临床试验。
Lancet Oncol. 2018 Jul;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4. Epub 2018 May 24.
8
CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.CDK4/6抑制剂在乳腺癌中的作用：反应机制与治疗失败原因
Curr Breast Cancer Rep. 2017 Mar;9(1):26-33. doi: 10.1007/s12609-017-0232-0. Epub 2017 Feb 1.
9
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.雌激素受体阳性乳腺癌对CDK4/6抑制的早期适应和获得性耐药
Cancer Res. 2016 Apr 15;76(8):2301-13. doi: 10.1158/0008-5472.CAN-15-0728. Epub 2016 Mar 28.
Zotero 插件